The world’s best-funded longevity biotech platform, Juvenescence, positions itself early to capitalise on the biggest and most complex industry in human history.
Juvenescence aims to confront ageing and age-related diseases head on, looking to drive scientific innovation with speed and agility to market. They are building an alliance of the world’s best scientists, physicians and investors to develop these new therapies and products.
Founded in 2016 by billionaire Jim Mellon and Dr Gregory Bailey (of Portage Biotech), Juvenescence aims to close 2021 with an IPO. The company already valued at $500M, finished it’s series C funding last April securing $56.9M, and recently acquired Portage Pharmaceuticals last March.
Juvenescence, lead by a trio of Jim Mellon (Chairman), Dr Gregory Baily (CEO), and Dr Declan Doogan (CMO) have developed a three pillar approach to achieve its goals:
- Understanding how the body regenerates itself, allowing them to help stimulate your body to regenerate healthier tissues and even organs.
- Developing therapies that prevent these same pathologies and disease states, shifting away from the sick-treat paradigm for good.
- Democratising these health breakthroughs for everyone by harnessing clinically-validated but more economically available therapies, such as supplements, and leveraging social media.
Juvenescence may currently be frontrunner, but a pack of well-backed and well-positioned competitors has formed close behind. Life Biosciences ($500M) lead by chairman David Sinclair and CEO Mehmood Khan (previously of PepsiCo) are the main competition, other players such as Sergey Young’s Longevity Vision Fund ($100M) and Google’s Calico are also operating and making waves in this new industry.
As this industry matures, the looming challenges are unprecedented, however so too are the opportunities. Juvenescence is well position to shape to young industry and will be a company to watch as they approach their IPO.
INVEST?
DEFINITELY
Eoghan‘s Blog 